Your browser is no longer supported. Please, upgrade your browser.
GTH Genetron Holdings Limited daily Stock Chart
Genetron Holdings Limited
Index- P/E- EPS (ttm)-4.64 Insider Own- Shs Outstand89.84M Perf Week-5.52%
Market Cap1.21B Forward P/E- EPS next Y-0.31 Insider Trans- Shs Float3.20M Perf Month3.60%
Income-95.70M PEG- EPS next Q-0.10 Inst Own11.60% Short Float10.20% Perf Quarter-
Sales42.40M P/S28.63 EPS this Y12.00% Inst Trans- Short Ratio0.39 Perf Half Y-
Book/sh- P/B- EPS next Y20.50% ROA- Target Price19.96 Perf Year-
Cash/sh0.01 P/C1517.17 EPS next 5Y- ROE- 52W Range11.09 - 17.71 Perf YTD-15.56%
Dividend- P/FCF- EPS past 5Y- ROI-90.80% 52W High-21.80% Beta-
Dividend %- Quick Ratio0.70 Sales past 5Y- Gross Margin44.40% 52W Low24.89% ATR0.86
Employees663 Current Ratio0.80 Sales Q/Q40.30% Oper. Margin- RSI (14)- Volatility4.73% 6.47%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.09 Prev Close13.51
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume831.50K Price13.85
Recom1.30 SMA20-3.03% SMA50-0.45% SMA200-0.45% Volume34,163 Change2.52%
Jul-14-20Initiated Canaccord Genuity Buy $19
Jul-14-20Initiated BTIG Research Buy $20
Aug-06-20 06:30AM  
Jul-29-20 04:39PM  
Jul-27-20 04:30PM  
Jun-30-20 08:55AM  
Jun-19-20 08:45AM  
Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early liver cancer screening services through laboratory developed tests services, such as HCCscreen, a proprietary assay for the early screening of liver cancer. It also provides in-vitro diagnostics products, including 8-gene Lung Cancer Assay, an IVD assay product based on semiconductor sequencing to detect lung cancer; Genetron 3D biochip reading instrument; IDH1/TERT gene assays for glioma; GENETRON S5, a semiconductor sequencer used in the field of gene detection; and Genetron S2000 that enables gene panel sequencing. In addition, the company develops ctDNA Lung Cancer assay for mutations in the epidermal growth factor receptor gene. It also offers development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies, hospitals, and research institutions worldwide. The company was founded in 2015 and is headquartered in Beijing, the People's Republic of China.